PrecivityAD2 is the first blood-based biomarker for people as young as 40 with cognitive symptoms
— PrecivityAD2 is the first blood-based biomarker for people as young as 40 with cognitive symptoms
by Judy George, Deputy Managing Editor, MedPage Today
August 21, 2026
• 2 min read
The FDA cleared the PrecivityAD2 blood test to help diagnose Alzheimer's disease as part of a standard clinical workup, C2N Diagnostics announced Thursday.
FDA Clears C2N Diagnostics’ PrecivityAD2® — First Alzheimer’s Blood Test for Adults with Cognitive Symptoms as Young as 40
FDA clears PrecivityAD2, Alzheimer's disease blood test for as early as age 40 years
FDA Clearance of C2N Diagnostics' PrecivityAD2 Blood Test Advances Precision Medicine for Alzheimer's, Building on Groundwork Laid by Early ADDF Investment
Alzheimer, FDA approva test del sangue per diagnosi dai 40 anni in su: “Accurato come scansioni cerebrali”
FDA Clears C2N Diagnostics’ PrecivityAD2® — First Alzheimer’s Blood Test for Adults with Cognitive Symptoms as Young as 40
The FDA has cleared PrecivityAD2, a single blood test designed to help health care professionals rule in or rule out an…
FDA Clearance of C2N Diagnostics' PrecivityAD2 Blood Test Advances Precision Medicine for Alzheimer's, Building on Groundwork…
The U.S. Food and Drug Administration on Friday approved a new blood test for the early detection of Alzheimer's disease in…
The U.S. Food and Drug Administration has cleared another blood test that could help doctors identify whether memory problems are…
Anthem Establishes Coverage of C2N Diagnostics’ PrecivityAD2® Blood Test for Alzheimer's Disease EvaluationMedical policy marks a…
